	US 11,884,732 B2
	Proteins binding HER2, NKG2D and CD16
Gregory P. Chang, Medford, MA (US); Ann F. Cheung, Lincoln, MA (US); William Haney, Wayland, MA (US); Bradley M. Lunde, Lebanon, NH (US); and Bianka Prinz, Lebanon, NH (US)
Assigned to Dragonfly Therapeutics, Inc., Waltham, MA (US)
Appl. No. 16/486,569
Filed by Dragonfly Therapeutics, Inc., Waltham, MA (US)
PCT Filed Feb. 20, 2018, PCT No. PCT/US2018/018771 § 371(c)(1), (2) Date Aug. 16, 2019, PCT Pub. No. WO2018/152518, PCT Pub. Date Aug. 23, 2018.
Claims priority of provisional application 62/461,146, filed on Feb. 20, 2017.
Prior Publication US 2020/0231678 A1, Jul. 23, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); C07K 16/32 (2006.01)

CPC C07K 16/2851 (2013.01) [A61P 35/00 (2018.01); C07K 16/283 (2013.01); C07K 16/32 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/524 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/732 (2013.01); C07K 2317/94 (2013.01)]

15 Claims

1. A protein comprising:

(a) a first antigen-binding site that binds NKG2D;

(b) a second antigen-binding site that binds HER2; and

(c) a first antibody Fc domain of human IgG1 or a portion thereof and a second antibody Fc domain of human IgG1 or a portion thereof that together are sufficient to bind CD16, wherein the first antibody Fc domain or the portion thereof and the second antibody Fc domain or the portion thereof comprise different amino acid mutations to promote heterodimerization,

wherein the first antigen-binding site comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:1 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:2.